Data / Drug companies / Golden State Medical Supply, Inc.
Golden State Medical Supply, Inc.: 502 products in the FDA NDC directory, labeler code 51407
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Golden State Medical Supply, Inc. (labeler code 51407) lists 502 products in the FDA National Drug Code Directory, covering 205 finished drugs by generic name. By type: 500 prescription drugs, 2 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on June 11, 2026.
The request: Watch Golden State Medical Supply, Inc. (FDA labeler code 51407): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 51407
- Products in commercial distribution
- 502
- Packages
- 697
- Finished drugs by generic name
- 205
- Prescription products
- 500
- Over the counter products
- 2
- Controlled substance products
- Schedule II 12, Schedule III 3, Schedule IV 15, Schedule V 12
- Flagged as original packager
- 69 of 69 products that carry the flag
- Started marketing in the last 12 months
- 5
- Products with a marketing end date set
- 19
- Earliest marketing start
- December 1, 1978
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 484 | 96.4% |
| New drug applications (NDA) | 9 | 1.8% |
| Authorized generics (NDA) | 8 | 1.6% |
| Other unapproved drugs | 1 | 0.2% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 500 | 99.6% |
| Over the counter drugs | 2 | 0.4% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 205 | 40.8% |
| Tablet, film coated | 106 | 21.1% |
| Capsule | 57 | 11.4% |
| Tablet, extended release | 33 | 6.6% |
| Capsule, extended release | 18 | 3.6% |
| Tablet, coated | 16 | 3.2% |
| Capsule, delayed release | 15 | 3% |
| Tablet, delayed release | 12 | 2.4% |
| Tablet, film coated, extended release | 7 | 1.4% |
| Tablet, orally disintegrating | 6 | 1.2% |
| Capsule, delayed release pellets | 5 | 1% |
| Solution | 4 | 0.8% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Sacubitril and valsartan | 51407-937 | Tablet, film coated | Generic drugs (ANDA) | June 11, 2026 |
| Sacubitril and valsartan | 51407-936 | Tablet, film coated | Generic drugs (ANDA) | June 11, 2026 |
| Sacubitril and valsartan | 51407-935 | Tablet, film coated | Generic drugs (ANDA) | June 11, 2026 |
| Nintedanib | 51407-985 | Capsule | Generic drugs (ANDA) | February 15, 2026 |
| Nintedanib | 51407-984 | Capsule | Generic drugs (ANDA) | February 15, 2026 |
| Ibuprofen | 51407-841 | Tablet | Generic drugs (ANDA) | September 26, 2025 |
| Ibuprofen | 51407-840 | Tablet | Generic drugs (ANDA) | September 26, 2025 |
| Ibuprofen | 51407-839 | Tablet | Generic drugs (ANDA) | September 26, 2025 |
| Doxepin hydrochloride | 51407-728 | Tablet | Generic drugs (ANDA) | August 6, 2025 |
| Doxepin hydrochloride | 51407-727 | Tablet | Generic drugs (ANDA) | August 6, 2025 |
| Ramipril | 51407-709 | Capsule | Generic drugs (ANDA) | July 8, 2025 |
| Ramipril | 51407-708 | Capsule | Generic drugs (ANDA) | July 8, 2025 |
| Ramipril | 51407-707 | Capsule | Generic drugs (ANDA) | July 8, 2025 |
| Ticagrelor | 51407-861 | Tablet | Generic drugs (ANDA) | May 1, 2025 |
| Sildenafil | 51407-987 | Tablet, film coated | Generic drugs (ANDA) | March 6, 2025 |
| LISINOPRIL and HYDROCHLOROTHIAZIDE | 51407-566 | Tablet | Generic drugs (ANDA) | February 15, 2025 |
| LISINOPRIL and HYDROCHLOROTHIAZIDE | 51407-565 | Tablet | Generic drugs (ANDA) | February 15, 2025 |
| LISINOPRIL and HYDROCHLOROTHIAZIDE | 51407-564 | Tablet | Generic drugs (ANDA) | February 15, 2025 |
| Omeprazole | 51407-943 | Capsule, delayed release | Generic drugs (ANDA) | December 27, 2024 |
| Fludrocortisone acetate | 51407-705 | Tablet | Generic drugs (ANDA) | October 16, 2024 |
| Trazodone Hydrochloride | 51407-947 | Tablet | Generic drugs (ANDA) | August 8, 2024 |
| Trazodone Hydrochloride | 51407-946 | Tablet | Generic drugs (ANDA) | August 8, 2024 |
| Eslicarbazepine Acetate | 51407-782 | Tablet | Generic drugs (ANDA) | December 7, 2023 |
| Eslicarbazepine Acetate | 51407-781 | Tablet | Generic drugs (ANDA) | December 7, 2023 |
| Eslicarbazepine Acetate | 51407-780 | Tablet | Generic drugs (ANDA) | December 7, 2023 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.